# AstraZeneca Licenses Ex-China Rights to Dizal's Zegfrovy (Sunvozertinib) for Lung Cancer for $600M Upfront

> partnership · REPORTED · 2026-07-14

AstraZeneca agreed to pay $600 million upfront for global ex-China rights to advance and commercialize Dizal Pharmaceutical's Zegfrovy, an oral irreversible EGFR inhibitor approved in the U.S. for locally advanced or metastatic non-small cell lung cancer.

About AstraZeneca: AstraZeneca is a global biopharmaceutical company focused on oncology, cardiovascular, renal, metabolism, and respiratory diseases, with a major commercial presence in targeted cancer therapies.

- Company: AstraZeneca
- Sector: oncology
- Primary source: https://www.thepharmaletter.com/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.